 Connection
Alexis Leal to Doxorubicin
This is a "connection" page, showing publications Alexis Leal has written about Doxorubicin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.263 |
|
|
|
-
Leal AD, Van Houten H, Sangaralingham L, Freedman RA, Jemal A, Neuman HB, Haddad TC, Mutter RW, Keegan THM, Mougalian SS, Loprinzi CL, Gross CP, Shah N, Ruddy KJ. Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens. Clin Breast Cancer. 2018 08; 18(4):e513-e520.
Score: 0.133
-
Leal AD, Kadakia KC, Looker S, Hilger C, Sorgatz K, Anderson K, Jacobson A, Grendahl D, Seisler D, Hobday T, Loprinzi CL. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 2014 May; 22(5):1313-7.
Score: 0.103
-
Hegerova LT, Leal AD, Grendahl DC, Seisler DK, Sorgatz KM, Anderson KJ, Hilger CR, Loprinzi CL. An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2015 Jan; 23(1):55-9.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|